The vice president of clinical development at Biohaven shed light on a newly initiated phase 3 study evaluating a promising agent for patients with all types of spinal muscular atrophy. [WATCH TIME: 2 minutes]
Lindsey Lee Lair, MD
Advertisement
Articles by Lindsey Lee Lair, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Parkinson Agent Tavapadon Shows Continued Efficacy, Safety in Phase 3 TEMPO-4 Trial
2
Elecsys pTau181 Test Cleared, Tividenofusp Alfa PDUFA Pushed Back, Phase 4 LOTUS Study Highlights Real-World Benefit of Trofinetide
3
Bilateral MR-Guided Focused Ultrasound Shows Benefit for Managing Parkinson Motor Complications in Phase 3 Trial
4
Ruptured vs Unruptured Aneurysms: Practical Decision Making with Guilherme Dabus, MD
5
